Special Issue "EGFR Family Signaling in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 December 2016)
Prof. Zhixiang Wang
Signal Transduction Research Group, Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
Website | E-Mail
Interests: ErbB receptors; cell signaling; protein trafficking; breast cancer; small GTPases and cell cycle
The epidermal growth factor receptor (EGFR) family (also known as ERBB family) of transmembrane receptor tyrosine kinases consists of four members including EGFR (ERBB1), HER2 (ERBB2), HER3 (ERBB3), and HER4 (ERBB4). EGFR family receptors were quickly linked to human cancer following their identification more than three decades ago. Mutation and overexpression of EGFR family have been closely associated with many types of cancers, including breast cancer, lung cancer, head and neck cancer, ovarian cancer, colorectal cancer, gastric cancer, glioma, melanoma, and medulloblastoma. EGFR family-mediated signal transduction in normal and cancer cells have been intensively studied and the vast signaling network downstream of EGFR family receptors have been largely revealed. EGFR family receptors have also been frequently targeted for cancer therapy and several agents targeting EGFR family receptors have been approved by the FDA and significantly improved treatment of the related cancers. However, novel signaling pathways and cell functions are continuously identified as regulated by EGFR family receptors. Due to the limitation and resistance of the currently available cancer therapies, EGFR family receptors are still intensively explored for developing novel therapies targeting various cancers. This Special Issue will cover the recent progress in all of the areas related to EGFR family signaling and cancer.
Prof. Dr. Zhixiang Wang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.